---
schema_version: "secwatch.filing_event.v1"
accession: "0001730463-26-000012"
form_type: "8-K"
ticker: "AUTL"
cik: "0001730463"
company_name: "Autolus Therapeutics plc"
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:54:21.783748+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Autolus reports preliminary 2025 AUCATZYL rev $75M; guides FY2026 $120-135M

## Summary
- Preliminary unaudited AUCATZYL net product revenue: Q4 2025 ~$24M, full year 2025 ~$75M.
- FY 2026 revenue guidance $120M-$135M; expects positive gross margin in 2026.
- Cash runway extended into Q4 2027 based on current operating plans.
- Pipeline: obe-cel Phase 2 CATULUS (pediatric B-ALL) and LUMINA (lupus nephritis) enrolling; BOBCAT (MS) and AUTO8 (AL amyloidosis) first patients dosed.
- UK commercial launch under NICE approval; manufacturing cost reduction initiatives underway.

## SEC filing metadata
- accession: 0001730463-26-000012
- form_type: 8-K
- ticker: AUTL
- cik: 0001730463
- company_name: Autolus Therapeutics plc
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000012/0001730463-26-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000012/autl-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730463-26-000012
- JSON: https://secwatch.observer/filing/0001730463-26-000012.json
- Plain text: https://secwatch.observer/filing/0001730463-26-000012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.